TScan Therapeutics, Inc. (TCRX) — Financial statements
Income statement, balance sheet, and cash flow for TScan Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 10↑266.7% | 3↓86.6% | 21↑55.5% | 14↑33.5% | 10 | |
| Cost of Revenue | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 7↑164.9% | 3↓86.6% | 21↑55.5% | 14↑33.5% | 10 | |
| Operating Expenses | ||||||
| R&D Expenses | 114↑6.3% | 107↑21.8% | 88↑47.4% | 60↑33.1% | 45 | |
| General & Administrative Expenses | 32↑8.2% | 30↑16.0% | 25↑25.3% | 20↑47.2% | 14 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 32↑8.2% | 30↑16.0% | 25↑25.3% | 20↑47.2% | 14 | |
| Other Expenses | -3↓493.7% | 0.73↓15.5% | 0.86 | 0.00 | 0.00 | |
| Operating Expenses | 143↑4.1% | 138↑20.2% | 115↑42.8% | 80↑36.4% | 59 | |
| Total Costs & Expenses | 146↑6.2% | 138↑20.2% | 115↑42.8% | 80↑36.4% | 59 | |
| Operating Results | ||||||
| Operating Income | -136↓0.7% | -135↓44.3% | -93↓40.3% | -67↓37.0% | -49 | |
| Depreciation & Amortization | 3↓30.2% | 4↓23.4% | 5↑4.4% | 5↑54.4% | 3 | |
| EBITDA | -133↓11.0% | -120↓49.5% | -80↓33.7% | -60↓32.3% | -45 | |
| EBIT | -136↓9.7% | -124↓44.9% | -85↓31.4% | -65↓33.8% | -49 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↓28.1% | 8↑98.4% | 4↑921.7% | 0.42↑2493.8% | 0.02 | |
| Interest Income | 9↓26.9% | 12↑50.8% | 8↑402.8% | 2↑9843.8% | 0.02 | |
| Interest Expense | 3↓24.2% | 4↓2.8% | 4↑219.6% | 1 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -11↓37.2% | -8↓402.8% | -2↓9843.8% | -0.02 | |
| Other Income / Expenses | 6↓17.4% | 7↑72.7% | 4↑921.7% | 0.42↑2493.8% | 0.02 | |
| Income Before Tax | -130↓1.8% | -127↓42.9% | -89↓34.7% | -66↓36.2% | -49 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -130↓1.8% | -127↓42.9% | -89↓34.7% | -66↓36.2% | -49 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -130↓1.8% | -127↓42.9% | -89↓34.7% | -66↓36.2% | -49 | |
| Bottom-Line Net Income | -130↓1.8% | -127↓42.9% | -89↓34.7% | -66↓36.2% | -49 | |
| EPS (Basic) | -1.00↑12.3% | -1.14↑16.2% | -1.36↑50.4% | -2.74↓35.0% | -2.03 | |
| EPS (Diluted) | -1.00↑12.3% | -1.14↑16.2% | -1.36↑50.4% | -2.74↓35.0% | -2.03 | |
| Weighted Average Shares | 130↑16.0% | 112↑70.7% | 66↑172.8% | 24↑0.6% | 24 | |
| Weighted Average Diluted Shares | 130↑16.0% | 112↑70.7% | 66↑172.8% | 24↑0.6% | 24 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.